home / stock / tcon / tcon news

TCON News and Press, TRACON Pharmaceuticals Inc. From 07/22/21

Stock Information
Company Name: TRACON Pharmaceuticals Inc.
Stock Symbol: TCON
Market: OTC
Website: traconpharma.com
Menu
TCON TCON Quote TCON Short TCON News TCON Articles TCON Message Board
Get TCON Alerts

News, Short Squeeze, Breakout and More Instantly...
TCON - NSPR, SPRT, KLDO among mid-day movers

Gainers: ImmunoPrecise Antibodies (IPA) +157%.India Globalization Capital (IGC) +74%.NRx Pharmaceuticals (NRXP) +56%.Universe Pharmaceuticals (UPC) +30%.Summit Wireless Technologies (WISA) +28%.Support.com (SPRT) +25%.Agrify Corporation (AGFY) +20%.PainReform (PRFX) +19%.Resources Connec...
TCON - ImmunoPrecise Antibodies, PainReform leads healthcare gainers; Seres Therapeutics, Jupiter Wellness among major losers

Gainers: ImmunoPrecise Antibodies (IPA) +88%, PainReform (PRFX) +48%, NRx Pharmaceuticals (NRXP) +30%, NeuroMetrix (NURO) +27%, Universe Pharmaceuticals (UPC) +18%.Losers: Seres Therapeutics (MCRB) -57%, Jupiter Wellness (JUPW)&...

TCON - Seres Therapeutics, IAMGOLD, PBF Energy among premarket losers' pack

Seres Therapeutics (MCRB) -57% after mid-stage ulcerative colitis study fails main goal.Jupiter Wellness (JUPW) -24% after raises $32.5M capital via stock and warrants offering.TRACON Pharmaceuticals (TCON) -23% after securing $15M capital raise.NETGEAR (NTGR)&#x...

TCON - TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced...
TCON - TRACON slumps 18% on $10M capital raise

TRACON Pharmaceuticals (TCON) enters into an underwriting agreement with H.C. Wainwright & Co. to purchase on a firm commitment basis 2,617,802 shares at a public offering price of $3.82 per share.Gross proceeds of ~$10MOffering is expected to close on or about July 26, 2021.The...

TCON - TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced...

TCON - TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...
TCON - TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TCON - TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and comme...

TCON - TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Company’s Phase 1 study of T...
Previous 10 Next 10